Literature DB >> 29285503

Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes.

Hidekatsu Yanai1.   

Abstract

Entities:  

Year:  2017        PMID： 29285503      PMCID： PMC5733321          DOI： 10.21037/atm.2017.09.22

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

Review 1.  Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.

Authors:  Matteo Monami; Ilaria Dicembrini; Edoardo Mannucci
Journal:  Acta Diabetol       Date:  2016-08-04       Impact factor: 4.280

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 3.  Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.

Authors:  Marwan Saad; Ahmed N Mahmoud; Islam Y Elgendy; Ahmed Abuzaid; Amr F Barakat; Akram Y Elgendy; Mohammad Al-Ani; Amgad Mentias; Ramez Nairooz; Anthony A Bavry; Debabrata Mukherjee
Journal:  Int J Cardiol       Date:  2016-11-09       Impact factor: 4.164

4.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

5.  CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

Authors:  Ele Ferrannini; Michael Mark; Eric Mayoux
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112

Review 6.  Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys.

Authors:  Motoaki Sano; Makoto Takei; Yasuyuki Shiraishi; Yoshihiko Suzuki
Journal:  J Clin Med Res       Date:  2016-10-26

7.  A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyayama
Journal:  J Clin Med Res       Date:  2016-12-31

8.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Authors:  Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici
Journal:  Circulation       Date:  2017-05-18       Impact factor: 29.690

Review 9.  The underlying mechanisms for development of hypertension in the metabolic syndrome.

Authors:  Hidekatsu Yanai; Yoshiharu Tomono; Kumie Ito; Nobuyuki Furutani; Hiroshi Yoshida; Norio Tada
Journal:  Nutr J       Date:  2008-04-17       Impact factor: 3.271

Review 10.  Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyama; Hidetaka Hamasaki; Hiroki Adachi; Sumie Moriyama; Reo Yoshikawa; Akahito Sako
Journal:  J Clin Med Res       Date:  2015-12-03
View more
  2 in total

1.  Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.

Authors:  Mariko Hakoshima; Hidekatsu Yanai; Kouki Kakuta; Hiroki Adachi
Journal:  J Clin Med Res       Date:  2018-04-13

Review 2.  Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.

Authors:  Hidekatsu Yanai; Mariko Hakoshima; Hiroki Adachi; Hisayuki Katsuyama
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.